Floatz logo

Bafisontamab

Advanced Lung Non-Small Cell Carcinoma

Shanghai EpimAb Biotherapeutics Co., Ltd.monoclonal_antibodyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Advanced Lung Non-Small Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Bms-907351
National Cancer Institute (NCI)
Phase 2BB
Danvatirsen
MedImmune LLC
Phase 2BB
gt103
Roswell Park Cancer Institute
Phase 2B
Carfilzomib
City of Hope Medical Center
Phase 1/2B
Nogapendekin Alfa
SWOG Cancer Research Network
Phase 2/3B

View all 14 →

Same molecule, other indications

Bafisontamab is also rated in:

colorectal cancerDormant
CCC
Indicative ·
52 / 100
View asset →
EGFR Mutation-Related TumorsDormant
CCC
Indicative ·
48 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →